Toshihiko Ohtomo

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.

Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.

Journal: BMC research notes

Published: October 01, 2019

Case-control Indian buffet process identifies biomarkers of response to Codrituzumab.

Case-control Indian buffet process identifies biomarkers of response to Codrituzumab.

Journal: BMC cancer

Published: November 20, 2018

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.

Journal: EJNMMI research

Published: December 11, 2017

Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

Journal: British journal of clinical pharmacology

Published: November 07, 2017

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.

Journal: Oncotarget

Published: January 11, 2017

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).

Journal: Cancer chemotherapy and pharmacology

Published: September 09, 2016

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Journal: Oncotarget

Published: June 16, 2016

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 27, 2015

High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.

High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.

Journal: International journal of cancer

Published: October 07, 2014

Circulating biomarkers in hepatocellular carcinoma.

Circulating biomarkers in hepatocellular carcinoma.

Journal: Cancer chemotherapy and pharmacology

Published: March 26, 2014

Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.

Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 14, 2013

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 31, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026